NeuroPace, Inc., a medical device company focused on improving the lives of individuals with epilepsy, has announced that an abstract from its Post-approval Study of the RNS System will be ...

Responsive neurostimulation (RNS) is an innovative treatment option for individuals suffering from drug-resistant epilepsy, particularly when traditional medications fail to control seizures.

NeuroPace (Nasdaq:NPCE) today announced that it intends to sell common stock in an underwritten public offering worth $65 ...

NeuroPace focuses on developing advanced medical devices for the treatment of neurological conditions, with a primary emphasis on epilepsy. The company's flagship product, the RNS System ...

“Like VNS for stroke patients, RNS marks a significant milestone in the treatment of epilepsy, providing life-changing options for patients,” Benitez adds. “We are at an inflection point in ...

One of the key developments is the potential expansion of indications for the RNS System. NeuroPace is targeting the treatment of idiopathic generalized epilepsy (IGE), with plans to submit an FDA ...

Additionally given a 30-day option to buy up to an extra 975,000 shares at the same price are underwriters. About $49.5 ...

Sean Lew recommended the responsive neurostimulation procedure, or RNS. “For epilepsy surgery, traditionally, the treatment is to find the part of the brain causing seizures and removing that ...

Epilepsy Surgery Market Poised for Steady Growth Driven by Advancements in Surgical Procedures and Rising Prevalence of Epilepsy.Pune, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Epilepsy Surgery Market Size & ...